The Pharma & Healthcare industry is of vital importance for human and economic development, providing a wide range of goods and services relevant to the promotion of health at all stages in the healthcare process – from prevention and treatment to rehabilitation and palliative care. It is one of the fastest-growing industries, supported by profound demographic changes, the rising incidence of non-communicable diseases, and surging per capita health spending in both developed and emerging markets. The industry is also one of the major innovators, with increasing expenditures on development of new molecules, biotechnology and adoption of new technologies that provide advanced healthcare and ensure the longevity of the population.
The Pharma & Healthcare industry comprises the manufacture of pharmaceuticals for human and veterinary use, medical equipment and related supplies. It also includes providers of ambulatory health services, medical and diagnostic laboratories, hospitals, and nursing and residential care facilities.
In the second quarter of 2018, China’s pharmaceutical and medicine production declined by 21.1% y/y to 749,000 tonnes, while their sales volume dropped by 22.7% y/y to 753,000 tonnes. This can be linked with the more stringent environmental ...View more details
The second quarter of 2018 witnessed a continuous growth of China’s healthcare sector. The growth was attributed to increasing demand for quality healthcare, stimulated by the country’s strong economic performance, rising incomes, ...View more details
Demand in the Malaysian Pharmaceuticals & Healthcare sector has been growing rapidly over the last few years as Malaysians have become more affluent and demanding with their healthcare needs. The aging population has also been seeing higher ...View more details
The first quarter of 2018 witnessed a continuous growth of China’s healthcare sector, stimulated by government policies and regulations. The country’s total spending on health and family planning reached RMB 442.6bn, up by 7.8% ...View more details
In Q4 2017, the government expenditure on health and family planning was RMB 276.7bn, representing a decrease of 7.5% y/y. Nevertheless, the healthcare expenditure in urban area was RMB 453.9bn, up by 2.8% y/y. For the whole year 2017, the government ...View more details
China is the world’s second largest pharmaceutical market after the US and the largest producer and exporter of active pharmaceutical ingredients (APIs) globally. Since it is the world’s most populous country, with a large share of ageing ...View more details
Argentina is among the top 20 pharmaceutical markets globally, ranking third in Latin America, with estimated drug retail sales of USD 6.1bn in 2017. The country also features a large and ageing population, a relatively developed public health system ...View more details
In the first two months of Q4 of 2017, the sales revenue of China’s pharmaceutical manufacturing sector went down by 17.8% y/y to RMB 445bn, as a result of the government’s tightening control over drug prices and distribution costs. ...View more details
Turkey’s health insurance coverage reaches 98.4% of the population, according to the OECD Health Statistics 2017. The state, through the Ministry of Health (MoH), is the main provider of health services in the country, which still has very low ...View more details
In 2012-2017 Chile’s total health expenditure rose at a CAGR of 11.6%, driven by a solid increase of government spending on healthcare. In 2017, Chile allocated 8.1% of its GDP on healthcare, a figure that is bound to grow in the short term. ...View more details